RUBRACA (rucaparib) tablets

Rubraca is a prescription medicine used in adults for: • the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer • the treatment of castration-resistant prostate cancer. Brand: RUBRACA (rucaparib) tablets, for oral use Initial U.S. Approval: 2016

Home | (rucaparib) tablets

RUBRACA (rucaparib) tablets Price In India and Overseas
RUBRACA (rucaparib) tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

RUBRACA (rucaparib) tablets

Rucaparib camsylate is approved to treat: Ovarian epithelial, fallopian tube, or primary peritoneal cancer, Prostate cancer. Rucaparib camsylate is also being studied in the treatment of other types of cancer.

Rubraca, A drug used to treat adults with certain types of prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. Rubraca blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Rubraca is a type of PARP inhibitor. Also called AG014699, PARP-1 inhibitor AG014699, and rucaparib camsylate.

Rucaparib Camsylate , A drug used to treat adults with certain types of prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. Rucaparib camsylate blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Rucaparib camsylate is a type of PARP inhibitor. Also called AG014699, PARP-1 inhibitor AG014699, and Rubraca.

Drug (Brand / Generic): RUBRACA / rucaparib
Current Indications: prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer
Marketed by:: Clovis Oncology, Inc
Approval Date: October 27, 2009

Available as (Form & Strength): Tablets: 200 mg, 250 mg, and 300 mg

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.